News & Analysis on Clinical Trial Services & Contract Research And Development
The non-clinical contract research organization (CRO) Citoxlab Group has acquired Solvo Biotechnology, a CRO specializing in drug transporters studies and the assessment of drug-drug interactions (DDI).
A lack of generic competition for Pfizer’s contraceptive Depo-Provera has influenced Amphastar’s decision to prioritise its pre-filled syringe version, says executive.
Trans-Hit Bio and Q&T Research have entered into an exclusive strategic partnership, which will provide biopharma customers with access to human biospecimens, for which there is “a great demand,” says exec.
Zelluna Immunotherapy has partnered with the CDMO MasSTherCell to develop its T-cell receptor (TCR) adoptive cell therapy platform with clinical trials expected to begin in 2019.
This year’s DCAT Week will focus on innovation in the pharmaceutical industry, with two new Executive Insights programs.
The industry is set up to accelerate the availability of new patient options in a “new era of medicine”– though robust intellectual property protection is critical to continued innovation.
A new method to predict the physical stability of drug candidates is attracting interest from pharmaceutical companies who could use the technology to de-risk early development.
The R&D playbook is evolving as the industry looks to break down the silos between clinical and commercial operations – bringing commercial voices to the earliest phases of asset development.
Partnering with CMOs makes sense for emerging biotechs, says Ardelyx exec James Kanter, who relies on networking and clear communication guidelines to manage third-party relationships.
CDMOs continue to take on a larger role supporting sponsors in the pharmaceutical industry, though new technology and changing requirements could shift the models in which they operate.
With GSK and Merck & Co. no longer on the books, Codexis is looking to secure its next CodeEvolver license deal.